TSXV:ICO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. More Details


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has iCo Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ICO is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: ICO's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of Canadian stocks.


Market Performance


7 Day Return

0%

ICO

11.2%

CA Biotechs

1.1%

CA Market


1 Year Return

-38.5%

ICO

86.2%

CA Biotechs

-1.5%

CA Market

Return vs Industry: ICO underperformed the Canadian Biotechs industry which returned 86.2% over the past year.

Return vs Market: ICO underperformed the Canadian Market which returned -1.5% over the past year.


Shareholder returns

ICOIndustryMarket
7 Day0%11.2%1.1%
30 Day-11.1%19.0%5.9%
90 Day-20.0%24.5%4.7%
1 Year-38.5%-38.5%86.2%86.2%2.1%-1.5%
3 Year0%0%11.0%11.0%11.0%0.2%
5 Year-11.1%-11.1%-3.9%-3.9%45.4%23.1%

Long-Term Price Volatility Vs. Market

How volatile is iCo Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is iCo Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether iCo Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as iCo Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ICO's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through iCo Therapeutics regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is iCo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iCo Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has iCo Therapeutics performed over the past 5 years?

-5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ICO is currently unprofitable.

Growing Profit Margin: ICO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ICO is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare ICO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.2%).


Return on Equity

High ROE: ICO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is iCo Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ICO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ICO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ICO is debt free.

Reducing Debt: ICO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ICO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ICO has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.3% each year.


Next Steps

Dividend

What is iCo Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ICO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ICO's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

William Jarosz (64 yo)

0.67

Tenure

Mr. William Wasyl Jarosz, J.D., has been Chief Executive Officer of iCo Therapeutics Inc. since March 9, 2020. He is a Senior Advisor at Cartesian Capital Group, LLC. He served as a Partner at the firm. Mr...


Leadership Team

NamePositionTenureCompensationOwnership
William Jarosz
Chairman of the Board & CEO0.67yrno data1.0%
CA$ 61.3k
Susan Koppy
President & Director4.92yrsCA$51.54kno data
Michael Liggett
CFO, Corporate Secretary & Director3.83yrsCA$50.35kno data
Peter Hnik
Chief Medical Officer & Director0.67yrCA$200.04kno data

2.5yrs

Average Tenure

62yo

Average Age

Experienced Management: ICO's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Jarosz
Chairman of the Board & CEO0.67yrno data1.0%
CA$ 61.3k
Susan Koppy
President & Director4.92yrsCA$51.54kno data
Michael Liggett
CFO, Corporate Secretary & Director3.83yrsCA$50.35kno data
Peter Hnik
Chief Medical Officer & Director0.67yrCA$200.04kno data
Julia Levy
Member of the Strategic Advisory Board15yrsno datano data
Richard Glickman
Member of the Strategic Advisory Board15yrsno datano data
David Boyer
Member of the Clinical Advisory Board14.08yrsno datano data
Jason Slakter
Member of Clinical Advisory Boardno datano datano data
Alan Bird
Member of the Clinical Advisory Board14.67yrsno datano data
Philip Rosenfeld
Member of Clinical Advisory Board14.42yrsno datano data
Andrea Leonardi
Member of the Clinical Advisory Boardno datano datano data
Donald Buell
Chairman of the Scientific Advisory Boardno datano datano data

14.1yrs

Average Tenure

62yo

Average Age

Experienced Board: ICO's board of directors are seasoned and experienced ( 14.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ICO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

iCo Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iCo Therapeutics Inc.
  • Ticker: ICO
  • Exchange: TSXV
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$6.150m
  • Shares outstanding: 153.75m
  • Website: https://www.icotherapeutics.com

Number of Employees


Location

  • iCo Therapeutics Inc.
  • 777 Hornby Street
  • 6th Floor
  • Vancouver
  • British Columbia
  • V6Z 1S4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ICOTSXV (TSX Venture Exchange)YesCommon SharesCACADJan 2008
ICOT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2008
0ITDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2008

Biography

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed product candida...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/24 00:11
End of Day Share Price2020/11/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.